MX2024006763A - Tratamiento de enfermedades neurológicas utilizando moduladores de los transcritos del gen unc13a. - Google Patents
Tratamiento de enfermedades neurológicas utilizando moduladores de los transcritos del gen unc13a.Info
- Publication number
- MX2024006763A MX2024006763A MX2024006763A MX2024006763A MX2024006763A MX 2024006763 A MX2024006763 A MX 2024006763A MX 2024006763 A MX2024006763 A MX 2024006763A MX 2024006763 A MX2024006763 A MX 2024006763A MX 2024006763 A MX2024006763 A MX 2024006763A
- Authority
- MX
- Mexico
- Prior art keywords
- unc13a
- neurological diseases
- modulators
- treatment
- gene transcripts
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title 1
- 101000768460 Homo sapiens Protein unc-13 homolog A Proteins 0.000 abstract 4
- 102100027901 Protein unc-13 homolog A Human genes 0.000 abstract 4
- 125000006850 spacer group Chemical group 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285786P | 2021-12-03 | 2021-12-03 | |
| US202263350206P | 2022-06-08 | 2022-06-08 | |
| US202263398987P | 2022-08-18 | 2022-08-18 | |
| PCT/US2022/051713 WO2023102225A2 (en) | 2021-12-03 | 2022-12-02 | Treatment of neurological diseases using modulators of unc13a gene transcripts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006763A true MX2024006763A (es) | 2024-08-15 |
Family
ID=86613080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006763A MX2024006763A (es) | 2021-12-03 | 2022-12-02 | Tratamiento de enfermedades neurológicas utilizando moduladores de los transcritos del gen unc13a. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250051766A1 (https=) |
| EP (1) | EP4441225A4 (https=) |
| JP (1) | JP2024543214A (https=) |
| KR (1) | KR20240129627A9 (https=) |
| CN (1) | CN119790152A (https=) |
| AU (1) | AU2022400851A1 (https=) |
| CA (1) | CA3239482A1 (https=) |
| CL (1) | CL2024001657A1 (https=) |
| CO (1) | CO2024008076A2 (https=) |
| CR (1) | CR20240269A (https=) |
| DO (1) | DOP2024000107A (https=) |
| IL (1) | IL313203A (https=) |
| JO (1) | JOP20240125A1 (https=) |
| MX (1) | MX2024006763A (https=) |
| PE (1) | PE20250677A1 (https=) |
| WO (1) | WO2023102225A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| AU2023356317A1 (en) * | 2022-10-05 | 2025-05-15 | Trace Neuroscience, Inc. | Unc13a antisense oligonucleotides and uses thereof |
| WO2024178223A1 (en) * | 2023-02-24 | 2024-08-29 | Northwestern University | Antisense oligonucleotides for preventing unc13a misplicing |
| US12612630B2 (en) | 2024-03-05 | 2026-04-28 | Takeda Pharmaceutical Company Limited | Compositions and methods for splicing modulation of UNC13A |
| WO2025255388A1 (en) * | 2024-06-05 | 2025-12-11 | Camp4 Therapeutics Corporation | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas |
| WO2026080323A1 (en) | 2024-10-09 | 2026-04-16 | Quralis Corporation | Treatment of neurological diseases using modulators of unc13a gene transcripts |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1470423A2 (en) * | 2001-11-05 | 2004-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Unc-13 in the modulation of neurotransmission and secretion events |
| EP2831232A4 (en) * | 2012-03-30 | 2015-11-04 | Univ Washington | METHOD FOR MODULATING TAU EXPRESSION TO REDUCE PROBLEMS AND MODIFY A NEURODEGENERATIVE SYNDROME |
| ES2788426T3 (es) * | 2014-06-16 | 2020-10-21 | Univ Johns Hopkins | Composiciones y métodos para la expresión de ARNs de guía de CRISPR utilizando el promotor de H1 |
| US20220008368A1 (en) * | 2018-11-15 | 2022-01-13 | President And Fellows Of Harvard College | Methods and compositions related to targeting ffar2 and ilc3 populations for the treatment of a gastrointestinal disease |
| EP4320236A1 (en) * | 2021-04-06 | 2024-02-14 | Maze Therapeutics, Inc. | Compositions and methods for treating tdp-43 proteinopathy |
-
2022
- 2022-12-02 US US18/715,644 patent/US20250051766A1/en active Pending
- 2022-12-02 JP JP2024532831A patent/JP2024543214A/ja active Pending
- 2022-12-02 PE PE2024001294A patent/PE20250677A1/es unknown
- 2022-12-02 CR CR20240269A patent/CR20240269A/es unknown
- 2022-12-02 EP EP22902264.5A patent/EP4441225A4/en active Pending
- 2022-12-02 CN CN202280090919.7A patent/CN119790152A/zh active Pending
- 2022-12-02 WO PCT/US2022/051713 patent/WO2023102225A2/en not_active Ceased
- 2022-12-02 IL IL313203A patent/IL313203A/en unknown
- 2022-12-02 KR KR1020247021710A patent/KR20240129627A9/ko active Pending
- 2022-12-02 AU AU2022400851A patent/AU2022400851A1/en active Pending
- 2022-12-02 MX MX2024006763A patent/MX2024006763A/es unknown
- 2022-12-02 CA CA3239482A patent/CA3239482A1/en active Pending
-
2024
- 2024-06-02 JO JOJO/P/2024/0125A patent/JOP20240125A1/ar unknown
- 2024-06-03 CL CL2024001657A patent/CL2024001657A1/es unknown
- 2024-06-03 DO DO2024000107A patent/DOP2024000107A/es unknown
- 2024-06-21 CO CONC2024/0008076A patent/CO2024008076A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20240269A (es) | 2024-09-13 |
| EP4441225A4 (en) | 2026-03-11 |
| DOP2024000107A (es) | 2024-09-30 |
| KR20240129627A9 (ko) | 2025-12-10 |
| JP2024543214A (ja) | 2024-11-19 |
| CO2024008076A2 (es) | 2024-11-18 |
| PE20250677A1 (es) | 2025-03-04 |
| CA3239482A1 (en) | 2023-06-08 |
| WO2023102225A3 (en) | 2024-03-28 |
| CL2024001657A1 (es) | 2024-12-20 |
| EP4441225A2 (en) | 2024-10-09 |
| KR20240129627A (ko) | 2024-08-27 |
| CN119790152A (zh) | 2025-04-08 |
| US20250051766A1 (en) | 2025-02-13 |
| WO2023102225A2 (en) | 2023-06-08 |
| IL313203A (en) | 2024-07-01 |
| AU2022400851A1 (en) | 2024-06-20 |
| JOP20240125A1 (ar) | 2024-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006763A (es) | Tratamiento de enfermedades neurológicas utilizando moduladores de los transcritos del gen unc13a. | |
| MX2025014278A (es) | Oligonucleotidos unc13a modificados | |
| CR20240003A (es) | Restos de administración terapéutica novedosos y usos de estos | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| BR0309888A (pt) | Tratamento intracraniano de distúrbios neuropsiquiátricos por neurotoxinas clostridiais tal como a toxina da botulina | |
| MX2024006612A (es) | Oligonucleotidos antisentido de cambio de empalme con estructuras quimicas modificadas. | |
| MX2010009767A (es) | Uso de celulas madre mesenquimales para tratar trastornos y enfermedades geneticas. | |
| EP2040548A4 (en) | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISEASES BY REINFORCING BETA-GLUCOCEREBROSIDASE ACTIVITY | |
| BR0014710A (pt) | Métodos para o tratamento de dor | |
| WO2001048190A8 (en) | Therapeutic uses of lna-modified oligonucleotides | |
| MX2012005131A (es) | Enfoques terapeuticos nuevos para tratar la enfermedad de alzheimer. | |
| WO2021247800A3 (en) | Treatment of neurological diseases using modulators of gene transcripts | |
| MX2009008413A (es) | Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica. | |
| MX2024000237A (es) | Arnip que inhibe la expresión del gen angptl3 y uso del mismo. | |
| MXPA05012196A (es) | Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos. | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| MX2023009324A (es) | Composiciones de arni de superóxido dismutasa 1 (sod1), y métodos de uso de este para el tratamiento o prevención de enfermedades neurodegenerativas relacionadas con superóxido dismutasa 1 (sod1). | |
| EP1960426A4 (en) | NEW NEUROTROPIC FACTOR PROTEIN AND APPLICATION THEREOF | |
| TW200510351A (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
| DE602004031199D1 (de) | Behandlung von igai-ablagerungserkrankungen | |
| Atsawasuwan et al. | Advances in orthodontic tooth movement: gene therapy and molecular biology aspect | |
| WO2003105761A3 (en) | Immunotoxin as a therapeutic agent and uses thereof | |
| WO2022256290A3 (en) | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | |
| Wen-Quan et al. | Comprehensive therapy of Chinese medicine in the treatment of senile sensorineural hearing loss: A clinical randomized controlled trial | |
| DE60204046D1 (de) | N-heterocyclylhydrazide als neurotrophe mittel |